113 related articles for article (PubMed ID: 18718658)
21. Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment.
Ishibashi M; Tamura H; Ogata K
Leuk Res; 2011 Nov; 35(11):1449-52. PubMed ID: 21757231
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
[TBL] [Abstract][Full Text] [Related]
23. Accelerated cellular senescence in myelodysplastic syndrome.
Wang YY; Cen JN; He J; Shen HJ; Liu DD; Yao L; Qi XF; Chen ZX
Exp Hematol; 2009 Nov; 37(11):1310-7. PubMed ID: 19748549
[TBL] [Abstract][Full Text] [Related]
24. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
[TBL] [Abstract][Full Text] [Related]
25. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma.
Liu TY; Chen CY; Tien HF; Lin CW
Histopathology; 2009 Jan; 54(2):214-20. PubMed ID: 19207946
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.
Cesana C; Klersy C; Brando B; Nosari A; Scarpati B; Scampini L; Molteni A; Nador G; Santoleri L; Formenti M; Valentini M; Mazzone A; Morra E; Cairoli R
Leuk Res; 2008 Nov; 32(11):1715-23. PubMed ID: 18456323
[TBL] [Abstract][Full Text] [Related]
27. Altered neutrophil maturation patterns that limit identification of myelodysplastic syndromes.
Monaghan SA; Surti U; Doty K; Craig FE
Cytometry B Clin Cytom; 2012 Jul; 82(4):217-28. PubMed ID: 22431481
[TBL] [Abstract][Full Text] [Related]
28. Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.
Lichtman MA
Oncologist; 2013; 18(9):973-80. PubMed ID: 23982763
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a new myeloid cell line with i(17q) as the sole chromosomal anomaly from the bone marrow of a patient with myelodysplastic syndrome.
Mizobuchi N; Takahashi I; Horimi T; Yamamoto M; Hamada K; Yorimitsu S; Kubonishi I
Acta Med Okayama; 1997 Aug; 51(4):227-32. PubMed ID: 9284971
[TBL] [Abstract][Full Text] [Related]
30. Mean diameter of nucleolar bodies in cultured human leukemic myeloblasts is mainly related to the S and G2 phase of the cell cycle.
Smetana K; Kuzelova K; Zápotocký M; Starková J; Hrkal Z; Trka J
Eur J Histochem; 2007; 51(4):269-74. PubMed ID: 18162456
[TBL] [Abstract][Full Text] [Related]
31. Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance.
Jevremovic D; Nanaa A; Geyer SM; Timm M; Azouz H; Hengel C; Reberg A; He R; Viswanatha D; Salama ME; Shi M; Olteanu H; Horna P; Otteson G; Greipp PT; Xie Z; Alkhateeb HB; Hogan W; Litzow M; Patnaik MM; Shah M; Al-Kali A; Nguyen PL
Am J Clin Pathol; 2022 Oct; 158(4):530-536. PubMed ID: 35938646
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
33. Label-free imaging and identification of typical cells of acute myeloid leukaemia and myelodysplastic syndrome by Raman microspectroscopy.
Vanna R; Ronchi P; Lenferink AT; Tresoldi C; Morasso C; Mehn D; Bedoni M; Picciolini S; Terstappen LW; Ciceri F; Otto C; Gramatica F
Analyst; 2015 Feb; 140(4):1054-64. PubMed ID: 25568900
[TBL] [Abstract][Full Text] [Related]
34. Unbalanced whole-arm translocation der(5;19)(p10;q10) is a novel and recurrent cytogenetic aberration in myelodysplastic syndrome.
Yamamoto K; Okamura A; Katayama Y; Shimoyama M; Matsui T
Leuk Res; 2009 Mar; 33(3):377-83. PubMed ID: 18829109
[TBL] [Abstract][Full Text] [Related]
35. T-cell immunoglobulin mucin-3 is underexpressed on myeloblasts in untreated myelodysplastic syndrome.
Garner K; Ten Eyck S; Craig FE; Roth CG
Leuk Lymphoma; 2014 Mar; 55(3):689-91. PubMed ID: 23725384
[No Abstract] [Full Text] [Related]
36. Myelodysplastic syndrome: from morphology to biology.
Albitar M; Zhou W; Giles F
Curr Hematol Rep; 2004 May; 3(3):159-64. PubMed ID: 15087062
[TBL] [Abstract][Full Text] [Related]
37. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
[TBL] [Abstract][Full Text] [Related]
38. [Progress in the study of CD34+ cells in myelodysplastic syndrome].
Zhang H; Shao Z
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):387-9. PubMed ID: 11189522
[No Abstract] [Full Text] [Related]
39. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
40. Platelet phagocytosis by granulopoietic precursors in a myelodysplastic syndrome overexpressing the P-selectin gene.
Morales-Camacho RM; Serrano-Chacón MD; Prats-Martín C; Vargas MT; Bernal R; Burillo-Sanz S
Br J Haematol; 2017 Apr; 177(2):171. PubMed ID: 28211570
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
